Rhode Island Hospital
- Type
- Teaching hospital
- Where
- Providence, RI
- Medicare CCN
- 410007
- Received
- $10,651,269 in 543 records, 2020 ($193,051 general, $10,458,218 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: RHODE ISLAND HOSPITAL Fuzzy (name and state)
- Federal award recipient: RHODE ISLAND HOSPITAL Fuzzy (name and state)
- Nonprofit: RHODE ISLAND HOSPITAL Fuzzy (name and state)
- Patent assignee: Rhode Island Hospital Fuzzy (name and state)
- Trademark owner: Rhode Island Hospital Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 50 | $193,051 |
| 2020 | Research payment | 493 | $10,458,218 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 493 | $10,458,218 |
| Grant | 7 | $103,909 |
| Education | 4 | $73,018 |
| Charitable Contribution | 2 | $7,375 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 27 | $6,700 |
| Gift | 5 | $1,838 |
| Royalty or License | 5 | $210 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Biohaven Pharmaceuticals, Inc. | $2,584 | Research payment | Cash or cash equivalent | A Seamless Phase 2A-B Randomized Double-blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of BHV-4157 i | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $1,079 | Research payment | In-kind items and services | A Phase 1, Open-label, Dose-escalation and Expansion Study of MEDI1191 Administered Intratumorally as Monotherapy and in | 2020 | |
| 2020-12-31 | Allergan, Inc. | $1,017 | Research payment | In-kind items and services | Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) | 2020 | |
| 2020-12-31 | Abbott Laboratories | $40 | Research payment | In-kind items and services | Proclaim XR IPG and BurstDR Device, Cardiac Arrhythmias and Heart Failure | Dorsal Spinal Cord Stimulation vs. Medical Management for Low Back Pain (DISTINCT) | 2020 |
| 2020-12-31 | Abbott Laboratories | $40 | Research payment | In-kind items and services | Proclaim XR IPG and BurstDR Device, Cardiac Arrhythmias and Heart Failure | Dorsal Spinal Cord Stimulation vs. Medical Management for Low Back Pain (DISTINCT) | 2020 |
| 2020-12-30 | PFIZER INC. | $72,033 | Research payment | Cash or cash equivalent | MYLOTARG Biological, ONCOLOGY | FRACTIONATED GEMTUZUMAB OZOGAMICIN FOLLOWED BY NONENGRAFTMENT DONOR LEUKOCYTE INFUSIONS FOR RELAPSEDREFRACTORY ACUTE MYE | 2020 |
| 2020-12-30 | ABBVIE INC. | $27,092 | Research payment | Cash or cash equivalent | M16-573 | 2020 | |
| 2020-12-30 | ABBVIE INC. | $2,199 | Research payment | Cash or cash equivalent | M15-913 | 2020 | |
| 2020-12-30 | ABBVIE INC. | $1,060 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M16-047 | 2020 |
| 2020-12-30 | GE HEALTHCARE | $699 | Education | Cash or cash equivalent | 2020 | ||
| 2020-12-29 | Smith+Nephew, Inc. | $380 | Gift | In-kind items and services | REFLECTION Device, Recon Hips | 2020 | |
| 2020-12-28 | Regeneron Pharmaceuticals, Inc. | $48,529 | Research payment | Cash or cash equivalent | A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies fo | 2020 | |
| 2020-12-22 | Genentech, Inc. | $15,242 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | PH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH2 | 2020 |
| 2020-12-21 | Eisai Inc. | $33,077 | Research payment | Cash or cash equivalent | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2020 | |
| 2020-12-21 | Genentech, Inc. | $9,875 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | ATEZOLIZUMAB IN MUSCLE INVASIVE BLADDER CANCER MIBC | 2020 |
| 2020-12-18 | PROGENICS PHARMACEUTICALS, INC. | $13,275 | Research payment | Cash or cash equivalent | Drug | Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prost | 2020 |
| 2020-12-18 | PROGENICS PHARMACEUTICALS, INC. | $3,500 | Research payment | Cash or cash equivalent | Drug | Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prost | 2020 |
| 2020-12-18 | Incyte Corporation | $1,386 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2020 | |
| 2020-12-17 | Regeneron Pharmaceuticals, Inc. | $145,881 | Research payment | Cash or cash equivalent | A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies fo | 2020 | |
| 2020-12-17 | Regeneron Pharmaceuticals, Inc. | $95,994 | Research payment | Cash or cash equivalent | A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies fo | 2020 | |
| 2020-12-17 | ABBVIE INC. | $18,851 | Research payment | Cash or cash equivalent | M15-570 | 2020 | |
| 2020-12-15 | PFIZER INC. | $104,392 | Research payment | In-kind items and services | MYLOTARG Biological, ONCOLOGY | FRACTIONATED GEMTUZUMAB OZOGAMICIN FOLLOWED BY NONENGRAFTMENT DONOR LEUKOCYTE INFUSIONS FOR RELAPSEDREFRACTORY ACUTE MYE | 2020 |
| 2020-12-15 | Eisai Inc. | $4,220 | Research payment | Cash or cash equivalent | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Sa | 2020 | |
| 2020-12-15 | Eisai Inc. | $1,620 | Research payment | Cash or cash equivalent | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Sa | 2020 | |
| 2020-12-14 | Allergan, Inc. | $9,000 | Research payment | Cash or cash equivalent | Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) | 2020 | |
| 2020-12-14 | Allergan, Inc. | $7,200 | Research payment | Cash or cash equivalent | Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) | 2020 | |
| 2020-12-14 | Gilead Sciences, Inc. | $6,947 | Research payment | Cash or cash equivalent | MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Effi | 2020 | |
| 2020-12-14 | Allergan, Inc. | $3,375 | Research payment | Cash or cash equivalent | Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) | 2020 | |
| 2020-12-14 | Allergan, Inc. | $1,500 | Research payment | Cash or cash equivalent | Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) | 2020 | |
| 2020-12-11 | Amgen Inc. | $10,200 | Research payment | In-kind items and services | Otezla Drug, Inflammation | Efficacy Safety Tolerability Study of Apremilast to Treat Early Oligoarticular PSA (PSA-013) | 2020 |
| 2020-12-10 | Regeneron Pharmaceuticals, Inc. | $12,300 | Research payment | Cash or cash equivalent | A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies fo | 2020 | |
| 2020-12-08 | Eisai Inc. | $49,077 | Research payment | Cash or cash equivalent | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2020 | |
| 2020-12-08 | PFIZER INC. | $11,657 | Research payment | Cash or cash equivalent | AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOS | 2020 | |
| 2020-12-07 | Regeneron Pharmaceuticals, Inc. | $385,956 | Research payment | Cash or cash equivalent | A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies fo | 2020 | |
| 2020-12-07 | Regeneron Pharmaceuticals, Inc. | $202,978 | Research payment | Cash or cash equivalent | A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies fo | 2020 | |
| 2020-12-07 | PFIZER INC. | $51,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-07 | AstraZeneca Pharmaceuticals LP | $2,913 | Research payment | Cash or cash equivalent | A Phase 1 First in Human Multicenter Open-label Doseescalation Study of IPH5201 as Monotherapy or in Combination with Du | 2020 | |
| 2020-12-03 | Regeneron Pharmaceuticals, Inc. | $528,521 | Research payment | Cash or cash equivalent | A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies fo | 2020 | |
| 2020-12-03 | ABBVIE INC. | $31,525 | Research payment | Cash or cash equivalent | M16-573 | 2020 | |
| 2020-12-03 | Amgen Inc. | $10,200 | Research payment | In-kind items and services | Otezla Drug, Inflammation | Efficacy Safety Tolerability Study of Apremilast to Treat Early Oligoarticular PSA (PSA-013) | 2020 |
| 2020-12-03 | Amgen Inc. | $10,200 | Research payment | In-kind items and services | Otezla Drug, Inflammation | Efficacy Safety Tolerability Study of Apremilast to Treat Early Oligoarticular PSA (PSA-013) | 2020 |
| 2020-12-03 | ABBVIE INC. | $9,414 | Research payment | Cash or cash equivalent | M16-438 | 2020 | |
| 2020-12-02 | PFIZER INC. | $1,750 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-02 | PFIZER INC. | $1,750 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-02 | PFIZER INC. | $1,750 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-02 | PFIZER INC. | $1,750 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-02 | Nevro Corp. | $400 | Research payment | Cash or cash equivalent | Senza Spinal Cord Stimulation System Device, Spinal Cord Stimulator | Post-Market Mulicenter Study Prospective | 2020 |
| 2020-12-01 | Regeneron Pharmaceuticals, Inc. | $6,650 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 | 2020 | |
| 2020-12-01 | Regeneron Pharmaceuticals, Inc. | $2,500 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 | 2020 | |
| 2020-12-01 | Eli Lilly and Company | $75 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATI | 2020 | |
| 2020-11-24 | Genentech, Inc. | $88,992 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | PH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH2 | 2020 |
| 2020-11-24 | Balt USA, LLC | $10,500 | Research payment | Cash or cash equivalent | The SQUID Trial for the Embolization of the Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma (STEM) | 2020 | |
| 2020-11-24 | CSL Behring | $6,500 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-11-23 | Bayer Healthcare Pharmaceuticals Inc. | $96,871 | Research payment | Cash or cash equivalent | Aliqopa Drug, Oncology | 060106 - Independent Research Grant (Bayer Product) | 2020 |
| 2020-11-23 | Genentech, Inc. | $2,778 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE III IPATASERTIB PLUS ABIRATERON IN MCRPC 1ST LINE | 2020 |
| 2020-11-22 | Eisai Inc. | $3,040 | Research payment | Cash or cash equivalent | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Sa | 2020 | |
| 2020-11-22 | Eisai Inc. | $3,040 | Research payment | Cash or cash equivalent | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Sa | 2020 | |
| 2020-11-20 | ABBVIE INC. | $12,885 | Research payment | Cash or cash equivalent | M15-570 | 2020 | |
| 2020-11-19 | Masimo Corporation | $500 | Research payment | Cash or cash equivalent | EMMA and ISA Device, Devices | Suner / Rhode Island Hospital / NIBp | 2020 |
| 2020-11-19 | Eli Lilly and Company | $105 | Research payment | In-kind items and services | ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY | 2020 | |
| 2020-11-18 | Gilead Sciences, Inc. | $1,863 | Research payment | Cash or cash equivalent | MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Effi | 2020 | |
| 2020-11-18 | Foundation Medicine, Inc. | $50 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FOUNDATIONONE LIQUID Device, ONCOLOGY | 2020 | |
| 2020-11-17 | Genentech, Inc. | $99,194 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | PH1B 2 TDB CHP POLA IN NHL FOR DOSE ESCALATION PH1B FOLLOWED BY 1L DLBCL FOR EXPANSION PH2 | 2020 |
| 2020-11-17 | PFIZER INC. | $55,702 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB00 | 2020 |
| 2020-11-17 | ABBVIE INC. | $4,500 | Research payment | Cash or cash equivalent | M15-570 | 2020 | |
| 2020-11-17 | ABBVIE INC. | $4,000 | Research payment | Cash or cash equivalent | M15-566 | 2020 | |
| 2020-11-16 | Regeneron Pharmaceuticals, Inc. | $155,796 | Research payment | Cash or cash equivalent | A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies fo | 2020 | |
| 2020-11-16 | Genentech, Inc. | $135,873 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | DLBCL SALVAGE SD PD OR CONSOLIDATION PR POST INDUCTION THERAPY 1L DLBCL IN ELDERLY FRAIL | 2020 |
| 2020-11-12 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-11-11 | Abbott Laboratories | $571 | Research payment | Cash or cash equivalent | CardioMEMS HF System Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2020 |
| 2020-11-10 | ABBVIE INC. | $11,500 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | M15-574 | 2020 |
| 2020-11-10 | Abbott Laboratories | $425 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent System Device, Vascular | XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients | 2020 |
| 2020-11-08 | Eisai Inc. | $2,600 | Research payment | Cash or cash equivalent | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Sa | 2020 | |
| 2020-11-05 | Genentech, Inc. | $168,369 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | PH1B 2 TDB CHP POLA IN NHL FOR DOSE ESCALATION PH1B FOLLOWED BY 1L DLBCL FOR EXPANSION PH2 | 2020 |
| 2020-11-04 | KLS-Martin L.P. | $10,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-11-03 | Incyte Corporation | $1,386 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2020 | |
| 2020-11-02 | EMD Serono, Inc. | $252 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) | 2020 |
| 2020-11-02 | EMD Serono, Inc. | $252 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) | 2020 |
| 2020-11-02 | EMD Serono, Inc. | $252 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) | 2020 |
| 2020-11-02 | EMD Serono, Inc. | $70 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) | 2020 |
| 2020-10-29 | Genentech, Inc. | $7,011 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | PH1B 2 TDB CHP POLA IN NHL FOR DOSE ESCALATION PH1B FOLLOWED BY 1L DLBCL FOR EXPANSION PH2 | 2020 |
| 2020-10-29 | ABBVIE INC. | $4,301 | Research payment | Cash or cash equivalent | M16-573 | 2020 | |
| 2020-10-29 | ABBVIE INC. | $1,283 | Research payment | Cash or cash equivalent | M15-913 | 2020 | |
| 2020-10-28 | Regeneron Pharmaceuticals, Inc. | $6,500 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | CEMIPLIMAB SURVIVORSHIP EPIDEMIOLOGY (CASE) STUDY | 2020 |
| 2020-10-27 | ABBVIE INC. | $9,018 | Research payment | Cash or cash equivalent | M15-570 | 2020 | |
| 2020-10-27 | Eli Lilly and Company | $4,992 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2020 | |
| 2020-10-26 | Genentech, Inc. | $178,376 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | DLBCL SALVAGE SD PD OR CONSOLIDATION PR POST INDUCTION THERAPY 1L DLBCL IN ELDERLY FRAIL | 2020 |
| 2020-10-26 | Genentech, Inc. | $115,204 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | DLBCL SALVAGE SD PD OR CONSOLIDATION PR POST INDUCTION THERAPY 1L DLBCL IN ELDERLY FRAIL | 2020 |
| 2020-10-26 | Genentech, Inc. | $12,800 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | DLBCL SALVAGE SD PD OR CONSOLIDATION PR POST INDUCTION THERAPY 1L DLBCL IN ELDERLY FRAIL | 2020 |
| 2020-10-26 | Gilead Sciences, Inc. | $4,795 | Research payment | Cash or cash equivalent | MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Effi | 2020 | |
| 2020-10-26 | Gilead Sciences, Inc. | $4,000 | Research payment | Cash or cash equivalent | MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Effi | 2020 | |
| 2020-10-23 | AKEBIA THERAPEUTICS INC | $2,288 | Research payment | Cash or cash equivalent | A PHASE 1B, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF VADADUSTAT IN | 2020 | |
| 2020-10-22 | Amgen Inc. | $20,400 | Research payment | In-kind items and services | Otezla Drug, Inflammation | Efficacy Safety Tolerability Study of Apremilast to Treat Early Oligoarticular PSA (PSA-013) | 2020 |
| 2020-10-22 | Regeneron Pharmaceuticals, Inc. | $18,725 | Research payment | Cash or cash equivalent | Characterization of the Molecular and Cellular Phenotype of Key Cell Immune Populations in COVID-19 Patients | 2020 | |
| 2020-10-22 | Amgen Inc. | $10,200 | Research payment | In-kind items and services | Otezla Drug, Inflammation | Efficacy Safety Tolerability Study of Apremilast to Treat Early Oligoarticular PSA (PSA-013) | 2020 |
| 2020-10-21 | Eisai Inc. | $3,750 | Research payment | Cash or cash equivalent | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Sa | 2020 | |
| 2020-10-21 | Eisai Inc. | $3,750 | Research payment | Cash or cash equivalent | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Sa | 2020 | |
| 2020-10-21 | Gilead Sciences, Inc. | $2,843 | Research payment | Cash or cash equivalent | MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Effi | 2020 | |
| 2020-10-19 | Regeneron Pharmaceuticals, Inc. | $81,050 | Research payment | Cash or cash equivalent | A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies fo | 2020 | |
| 2020-10-19 | Regeneron Pharmaceuticals, Inc. | $57,099 | Research payment | Cash or cash equivalent | A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies fo | 2020 | |
| 2020-10-16 | ABBVIE INC. | $1,500 | Research payment | Cash or cash equivalent | M15-566 | 2020 | |
| 2020-10-15 | Eisai Inc. | $55,389 | Research payment | Cash or cash equivalent | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2020 | |
| 2020-10-15 | Eisai Inc. | $12,500 | Research payment | Cash or cash equivalent | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Sa | 2020 | |
| 2020-10-15 | Eisai Inc. | $12,500 | Research payment | Cash or cash equivalent | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Sa | 2020 | |
| 2020-10-15 | GenMark Diagnostics, Inc. | $8,375 | Research payment | Cash or cash equivalent | ePlex Device, Devices | Evaluation of ePlex Blood Culture Identification Panels | 2020 |
| 2020-10-14 | SEAGEN INC. | $104,226 | Research payment | Cash or cash equivalent | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | 2020 | |
| 2020-10-14 | Merck Sharp & Dohme LLC | $32,400 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1 Study of CDX-1140, a Fully Human Agonist anti-CD40 Monoclonal Antibody, as Monotherapy or in Combination in Pa | 2020 |
| 2020-10-14 | Takeda Pharmaceuticals U.S.A., Inc. | $25 | Research payment | Cash or cash equivalent | NATPARA (PARATHYROID HORMONE) Drug, INTERNAL MEDICINE | PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM | 2020 |
| 2020-10-12 | AKEBIA THERAPEUTICS INC | $3,485 | Research payment | Cash or cash equivalent | PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE M | 2020 | |
| 2020-10-09 | JAZZ PHARMACEUTICALS INC. | $127,029 | Research payment | In-kind items and services | VYXEOS Drug, HEMATOLOGY/ONCOLOGY | A STUDY TO COMPARE STANDARD CHEMOTHERAPY TO THERAPY WITH CPX-351 AND/OR GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED A | 2020 |
| 2020-10-08 | Incyte Corporation | $38 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2020 | |
| 2020-10-08 | Incyte Corporation | $23 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2020 | |
| 2020-10-08 | Incyte Corporation | $23 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2020 | |
| 2020-10-06 | ABBVIE INC. | $69,340 | Research payment | Cash or cash equivalent | M16-298 | 2020 | |
| 2020-10-01 | BioFire Diagnostics, LLC | $22,500 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI STA Pivotal Study | 2020 |
| 2020-10-01 | ABBVIE INC. | $20,143 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M16-047 | 2020 |
| 2020-10-01 | Genentech, Inc. | $13,832 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | APDL1 A PHASE II OPEN LABEL RANDOMIZED IN PATS WITH NSCLC | 2020 |
| 2020-09-30 | ABBVIE INC. | $17,912 | Research payment | Cash or cash equivalent | M16-573 | 2020 | |
| 2020-09-30 | ABBVIE INC. | $7,330 | Research payment | Cash or cash equivalent | M15-566 | 2020 | |
| 2020-09-30 | ABBVIE INC. | $6,633 | Research payment | Cash or cash equivalent | M16-438 | 2020 | |
| 2020-09-30 | ABBVIE INC. | $427 | Research payment | Cash or cash equivalent | M15-913 | 2020 | |
| 2020-09-29 | Bio-Rad Laboratories, Inc. | $988 | Gift | Cash or cash equivalent | Real Time PCR Device, Real Time PCR | 2020 | |
| 2020-09-29 | Bio-Rad Laboratories, Inc. | $169 | Gift | Cash or cash equivalent | Digital PCR Assays Device, PCR | 2020 | |
| 2020-09-28 | ABBVIE INC. | $26,167 | Research payment | Cash or cash equivalent | M15-570 | 2020 | |
| 2020-09-25 | Incyte Corporation | $2,925 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2020 | |
| 2020-09-24 | AKEBIA THERAPEUTICS INC | $400 | Research payment | Cash or cash equivalent | A PHASE 1B, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF VADADUSTAT IN | 2020 | |
| 2020-09-23 | Gilead Sciences, Inc. | $1,927 | Research payment | Cash or cash equivalent | MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Effi | 2020 | |
| 2020-09-22 | Alexion Pharmaceuticals, Inc. | $1,000 | Research payment | Cash or cash equivalent | Strensiq Drug, Endocrinology | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2020 |
| 2020-09-21 | Eisai Inc. | $27,306 | Research payment | Cash or cash equivalent | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2020 | |
| 2020-09-21 | PFIZER INC. | $1,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-09-18 | PFIZER INC. | $1,000 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-09-18 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-09-17 | ABBVIE INC. | $12,813 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M16-047 | 2020 |
| 2020-09-17 | PFIZER INC. | $3,000 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 | 2020 | |
| 2020-09-16 | BioFire Diagnostics, LLC | $2,937 | Research payment | Cash or cash equivalent | FilmArray System Device, Clinical Diagnostics | FilmArray GI STA Pivotal Study | 2020 |
| 2020-09-15 | Bayer Healthcare Pharmaceuticals Inc. | $12,990 | Research payment | Cash or cash equivalent | Non-Covered | Combo with PD-1 inhibitor | 2020 |
| 2020-09-11 | BioFire Diagnostics, LLC | $4,689 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI STA Pivotal Study | 2020 |
| 2020-09-10 | AstraZeneca Pharmaceuticals LP | $13,500 | Research payment | Cash or cash equivalent | IMFINZI Drug, Oncology | A Phase 2, Open-label, Randomized, Multicenter, Platform Study of Novel Oncology Therapies in Combination with Adjuvant | 2020 |
| 2020-09-10 | CSL Behring | $764 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-09-10 | GE HEALTHCARE | $699 | Education | Cash or cash equivalent | 2020 | ||
| 2020-09-09 | Functional Neuromodulation Inc | $7,000 | Research payment | Cash or cash equivalent | Device, Deep Brain Stimulator | ADvance II | 2020 |
| 2020-09-08 | PTC Therapeutics, Inc. | $2,307 | Research payment | Cash or cash equivalent | PHASE 1B STUDY OF PTC299 IN RELAPSED/REFRACTORY ACUTE LEUKEMIAS | 2020 | |
| 2020-09-08 | PTC Therapeutics, Inc. | $2,010 | Research payment | Cash or cash equivalent | PHASE 1B STUDY OF PTC299 IN RELAPSED/REFRACTORY ACUTE LEUKEMIAS | 2020 | |
| 2020-09-08 | Incyte Corporation | $46 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2020 | |
| 2020-09-08 | Incyte Corporation | $45 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2020 | |
| 2020-09-08 | Incyte Corporation | $35 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2020 | |
| 2020-09-08 | Incyte Corporation | $30 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2020 | |
| 2020-09-08 | Incyte Corporation | $2 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2020 | |
| 2020-09-08 | Incyte Corporation | $2 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2020 | |
| 2020-09-08 | Incyte Corporation | $1 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2020 | |
| 2020-09-03 | Biogen, Inc. | $194,496 | Research payment | Cash or cash equivalent | A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Pa | 2020 | |
| 2020-09-02 | ABBVIE INC. | $861 | Research payment | Cash or cash equivalent | M15-566 | 2020 | |
| 2020-08-31 | ABBVIE INC. | $14,011 | Research payment | Cash or cash equivalent | M16-573 | 2020 | |
| 2020-08-31 | ABBVIE INC. | $11,278 | Research payment | Cash or cash equivalent | M16-438 | 2020 | |
| 2020-08-31 | US ENDOSCOPY | $460 | Research payment | Cash or cash equivalent | TruFreeze Device, 78 GASTROENTEROLOGY | 2020 | |
| 2020-08-28 | ABBVIE INC. | $855 | Research payment | Cash or cash equivalent | M15-913 | 2020 | |
| 2020-08-27 | Celgene Corporation | $163,813 | Research payment | Cash or cash equivalent | (AZA-JMML-001) PhII Azacitidine Open-label PK, Pharmacodynamics, Safety, Activity vs Historical Controls in Peds With ND | 2020 | |
| 2020-08-26 | AstraZeneca Pharmaceuticals LP | $81,819 | Research payment | Cash or cash equivalent | An Open-label Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Effic | 2020 | |
| 2020-08-24 | ABBVIE INC. | $8,270 | Research payment | Cash or cash equivalent | M15-570 | 2020 | |
| 2020-08-21 | PFIZER INC. | $3,000 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 | 2020 | |
| 2020-08-19 | Eisai Inc. | $46,978 | Research payment | Cash or cash equivalent | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2020 | |
| 2020-08-19 | KLS-Martin L.P. | $10,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-08-19 | PFIZER INC. | $9,000 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 | 2020 | |
| 2020-08-19 | Gilead Sciences, Inc. | $1,228 | Research payment | Cash or cash equivalent | MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Effi | 2020 | |
| 2020-08-17 | Merck Sharp & Dohme LLC | $32,400 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1 Study of CDX-1140, a Fully Human Agonist anti-CD40 Monoclonal Antibody, as Monotherapy or in Combination in Pa | 2020 |
| 2020-08-14 | E.R. Squibb & Sons, L.L.C. | $298,500 | Research payment | Cash or cash equivalent | Multidimensional IO markers of Response and Resistance To Checkpoint Inhibition in Cancer Patients | 2020 | |
| 2020-08-12 | EMD Serono, Inc. | $68,314 | Research payment | Cash or cash equivalent | MSB0010718C | A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biologic | 2020 |
| 2020-08-11 | Allergan, Inc. | $54,724 | Research payment | Cash or cash equivalent | DEVELOPMENT OF A DIAGNOSTIC TEST FOR MALIGNANT (BIA-ALCL) SEROMAS | 2020 | |
| 2020-08-07 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-08-07 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-08-06 | ABBVIE INC. | $1,117 | Research payment | Cash or cash equivalent | CREON Drug, ENDOCRINOLOGY | P12-792 | 2020 |
| 2020-08-06 | VIVUS LLC | $375 | Research payment | Cash or cash equivalent | PANCREAZE Drug, CYSTIC FIBROSIS | Long-term Study in US Cystic Fibrosis | 2020 |
| 2020-08-05 | Eisai Inc. | $4,444 | Research payment | Cash or cash equivalent | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2020 | |
| 2020-08-04 | ABBVIE INC. | $43,186 | Research payment | Cash or cash equivalent | M16-573 | 2020 | |
| 2020-08-04 | ABBVIE INC. | $17,915 | Research payment | Cash or cash equivalent | M16-438 | 2020 | |
| 2020-08-04 | Amgen Inc. | $1,751 | Research payment | Cash or cash equivalent | Otezla Drug, Inflammation | Efficacy Safety Tolerability Study of Apremilast to Treat Early Oligoarticular PSA (PSA-013) | 2020 |
| 2020-08-03 | F. Hoffmann-La Roche AG | $61,333 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC NON SQUAMOUS DX ALL COMER ABRAXANE | 2020 |
| 2020-08-03 | Incyte Corporation | $2,773 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2020 | |
| 2020-07-31 | ABBVIE INC. | $11,856 | Research payment | Cash or cash equivalent | M15-566 | 2020 | |
| 2020-07-30 | Bayer Healthcare Pharmaceuticals Inc. | $40,083 | Research payment | Cash or cash equivalent | Non-Covered | Combo with PD-1 inhibitor | 2020 |
| 2020-07-29 | ABBVIE INC. | $12,551 | Research payment | Cash or cash equivalent | M15-570 | 2020 | |
| 2020-07-29 | Regeneron Pharmaceuticals, Inc. | $10,851 | Research payment | Cash or cash equivalent | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2020 | |
| 2020-07-28 | BioFire Diagnostics, LLC | $9,300 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI STA Pivotal Study | 2020 |
| 2020-07-28 | Alexion Pharmaceuticals, Inc. | $400 | Research payment | Cash or cash equivalent | Strensiq Drug, Endocrinology | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2020 |
| 2020-07-28 | Alexion Pharmaceuticals, Inc. | $320 | Research payment | Cash or cash equivalent | Strensiq Drug, Endocrinology | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2020 |
| 2020-07-26 | AstraZeneca Pharmaceuticals LP | $3,900 | Research payment | Cash or cash equivalent | LYNPARZA Drug, Oncology | Olaparib Prior to Radical Prostatectomy For Patients with Locally Advanced Prostate Cancer and Defects in DNA Repair Gen | 2020 |
| 2020-07-24 | ABBVIE INC. | $1,500 | Research payment | Cash or cash equivalent | M15-570 | 2020 | |
| 2020-07-23 | Genentech, Inc. | $11,750 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | TENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS | 2020 |
| 2020-07-22 | Gilead Sciences, Inc. | $4,404 | Research payment | Cash or cash equivalent | MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Effi | 2020 | |
| 2020-07-21 | EMD Serono, Inc. | $252 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) | 2020 |
| 2020-07-20 | Eisai Inc. | $26,959 | Research payment | Cash or cash equivalent | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2020 | |
| 2020-07-20 | Amgen Inc. | $20,400 | Research payment | In-kind items and services | Otezla Drug, Inflammation | Efficacy Safety Tolerability Study of Apremilast to Treat Early Oligoarticular PSA (PSA-013) | 2020 |
| 2020-07-16 | Davol Inc. | $7,000 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-07-16 | Celgene Corporation | $1,875 | Research payment | Cash or cash equivalent | Abraxane Drug, Oncology | BrUOG P318: FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial | 2020 |
| 2020-07-15 | Adaptive Biotechnologies Corporation | $24,300 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | 297381-29 | 2020 |
| 2020-07-13 | AKEBIA THERAPEUTICS INC | $6,038 | Research payment | Cash or cash equivalent | PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE C | 2020 | |
| 2020-07-09 | ABBVIE INC. | $8,625 | Research payment | Cash or cash equivalent | M14-360 | 2020 | |
| 2020-07-07 | Fujirebio Diagnostics, Incorporated | $1,750 | Research payment | Cash or cash equivalent | Device, In-vitro diagnostic reagents | Brain Natriuretic Peptide | 2020 |
| 2020-07-07 | Siemens Medical Solutions USA, Inc. | $375 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-07-02 | Abbott Laboratories | $787 | Research payment | Cash or cash equivalent | ABSORB Device, Vascular | ABSORB III Randomized Controlled Trial (RCT) (ABSORB-III) | 2020 |
The latest 200 records of 543.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Providence, RI, county Providence County, RI, state Rhode Island; placed by its city name.
| Measure | Place (city or town) Providence, RI | County Providence County, RI | State Rhode Island |
|---|---|---|---|
| Population B01003 | 191,767 | 664,854 | 1,101,801 |
| Population, 2020 census P1 | 190,934 | 660,741 | 1,097,379 |
| Median age B01002 | 32.8 | 38.0 | 40.6 |
| Under 18 B01001 | 20.1% | 20.1% | 18.8% |
| 65 and over B01001 | 11.6% | 16.3% | 18.7% |
| Households B11001 | 71,497 | 259,210 | 441,570 |
| Foreign born B05002 | 33.5% | 20.9% | 15.3% |
| Median household income B19013 | $68,119 | $78,787 | $87,796 |
| Median family income B19113 | $80,994 | $99,120 | $112,375 |
| Per capita income B19301 | $37,138 | $41,523 | $47,150 |
| Poverty rate B17001 | 20.7% | 13.4% | 11.2% |
| Unemployment rate B23025 | 8.2% | 6.6% | 5.8% |
| Civilian labor force B23025 | 101,717 | 358,122 | 594,253 |
| Mean commute (minutes) B08013 | 25.0 | 25.9 | 25.5 |
| Bachelor's degree or higher B15003 | 34.6% | 32.3% | 37.7% |
| Housing units B25001 | 79,423 | 277,740 | 485,932 |
| Owner-occupied B25003 | 41.4% | 56.9% | 63.6% |
| Renters B25003 | 58.6% | 43.1% | 36.4% |
| Median home value B25077 | $362,200 | $373,600 | $404,200 |
| Median gross rent B25064 | $1,408 | $1,312 | $1,342 |
| White, not Hispanic B03002 | 33.1% | 56.5% | 68.0% |
| Black B03002 | 10.2% | 7.0% | 4.9% |
| Hispanic or Latino B03002 | 45.3% | 25.6% | 17.7% |
| Asian B03002 | 6.2% | 4.2% | 3.5% |
| American Indian and Alaska Native B03002 | 0.3% | 0.2% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Providence, RI.
Comments